Epidermal growth factor receptor tyrosine kinase inhibitors

被引：76

作者：

Wakeling, AE ^{[1
]}

机构：

[1] AstrZeneca Pharmaceut, Canc & Infect Res, Macclesfield SK10 4TG, Cheshire, England

来源：

CURRENT OPINION IN PHARMACOLOGY | 2002年 / 2卷 / 04期

关键词：

D O I：

10.1016/S1471-4892(02)00183-2

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Clinical trials of selective small-molecule, inhibitors of epidermal growth factor receptor tyrosine kinase activity have shown that these targeted inhibitors of proliferative signal transduction provide well-tolerated antitumour activity in patients. Preclinical pharmacology studies illustrate the potential use of these new cancer therapeutics in combination with chemotherapy, radiotherapy and hormone therapy, and in chemoprevention, in a spectrum of solid human tumours.

引用

页码：382 / 387

页数：6

共 48 条

[1] Albanell J, 2001, CANCER RES, V61, P6500
[2] Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
Albanell, J
Rojo, F
Averbuch, S
Feyereislova, A
Mascaro, JM
Herbst, R
LoRusso, P
Rischin, D
Sauleda, S
Gee, J
Nicholson, RI
Baselga, J
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 110 - 124
[3] ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression
Anderson, NG
Ahmad, T
Chan, K
Dobson, R
Bundred, NJ
[J]. INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (06) : 774 - 782
[4] HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer
Arteaga, CL
Moulder, SL
Yakes, FM
[J]. SEMINARS IN ONCOLOGY, 2002, 29 (03) : 4 - 10
[5] Averbuch SD, 2002, CLIN CANCER RES, V8, P1
[6] Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer
Barker, AJ
Gibson, KH
Grundy, W
Godfrey, AA
Barlow, JJ
Healy, MP
Woodburn, JR
Ashton, SE
Curry, BJ
Scarlett, L
Henthorn, L
Richards, L
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) : 1911 - 1914
[7] ZD1839 ('Iressa')1,2 as an anticancer agent
Baselga, J
Averbuch, SD
[J]. DRUGS, 2000, 60 (Suppl 1) : 33 - 40
[8] Baselga J, 2001, CLIN CANCER RES, V7, p3780S
[9] Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family
Bishop, PC
Myers, T
Robey, R
Fry, DW
Liu, ET
Blagosklonny, MV
Bates, SE
[J]. ONCOGENE, 2002, 21 (01) : 119 - 127
[10] The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells
Bowers, G
Reardon, D
Hewitt, T
Dent, P
Mikkelsen, RB
Valerie, K
Lammering, G
Amir, C
Schmidt-Ullrich, RK
[J]. ONCOGENE, 2001, 20 (11) : 1388 - 1397

← 1 2 3 4 5 →